Hope S Rugo Selected Research

Exanthema (Rash)

6/2023	Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
2/2022	A multidisciplinary approach to optimizing care of patients treated with alpelisib.
1/2019	Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
1/2019	Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
1/2017	Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hope S Rugo Research Topics

Disease

295	Breast Neoplasms (Breast Cancer) 05/2024 - 12/2003
162	Neoplasms (Cancer) 06/2024 - 12/2003
53	Triple Negative Breast Neoplasms 04/2024 - 01/2010
24	Neoplasm Metastasis (Metastasis) 02/2024 - 01/2008
23	Disease Progression 12/2023 - 09/2012
19	Neutropenia 10/2023 - 06/2013
16	Diarrhea 10/2023 - 01/2017
15	Fatigue 02/2024 - 02/2012
13	Nausea 01/2023 - 02/2013
12	Vomiting 01/2023 - 02/2013
11	Pathologic Complete Response 12/2023 - 01/2020
10	Stomatitis 02/2023 - 06/2004
9	Anemia 01/2022 - 02/2012
8	Pneumonia (Pneumonitis) 01/2023 - 02/2012
8	Brain Neoplasms (Brain Tumor) 06/2022 - 01/2009
8	Circulating Neoplastic Cells 01/2022 - 01/2017
8	Febrile Neutropenia 01/2022 - 10/2013
7	Alopecia (Baldness) 01/2023 - 01/2017
6	Hyperglycemia 01/2024 - 02/2012
6	Hypertension (High Blood Pressure) 10/2018 - 01/2004
5	Exanthema (Rash) 06/2023 - 01/2017
5	Infections 01/2023 - 01/2019
5	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 01/2021
5	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 07/2015
4	Residual Neoplasm 03/2024 - 02/2012
4	Leukemia 01/2021 - 06/2004
4	Proteinuria 01/2016 - 01/2004

Drug/Important Bio-Agent (IBA)

131	Hormones (Hormone)IBA 05/2024 - 04/2007
62	ErbB Receptors (EGF Receptor)IBA 01/2024 - 02/2007
39	palbociclibIBA 04/2024 - 01/2016
35	Trastuzumab (Herceptin)FDA Link 12/2023 - 02/2007
31	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2008
28	Aromatase InhibitorsIBA 03/2024 - 07/2007
27	Paclitaxel (Taxol)FDA LinkGeneric 12/2023 - 10/2006
25	human ERBB2 proteinIBA 02/2024 - 02/2011
21	taxaneIBA 10/2023 - 02/2005
20	Estrogen ReceptorsIBA 04/2024 - 06/2009
20	Everolimus FDA Link 12/2023 - 06/2009
19	Capecitabine (Xeloda)FDA Link 10/2022 - 02/2005
19	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2004
18	Letrozole (Femara)FDA LinkGeneric 01/2024 - 06/2009
18	Cyclin-Dependent Kinase 4IBA 11/2023 - 02/2016
17	Epidermal Growth Factor (EGF)IBA 05/2024 - 03/2010
16	exemestane (Aromasin)FDA Link 12/2023 - 02/2012
15	Fulvestrant (Faslodex)FDA Link 01/2024 - 02/2016
14	sacituzumab govitecanIBA 05/2024 - 01/2019
13	abemaciclibIBA 04/2024 - 02/2016
13	AnthracyclinesIBA 07/2019 - 02/2005
12	pembrolizumabIBA 12/2023 - 08/2017
11	Gemcitabine FDA Link 10/2022 - 05/2013
11	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 04/2005
11	Estrogens (Estrogen)FDA Link 05/2020 - 04/2007
11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 01/2004
10	AlpelisibIBA 01/2024 - 01/2018
10	Tyrosine Kinase InhibitorsIBA 02/2023 - 10/2006
10	Lapatinib (GW572016)FDA Link 01/2020 - 02/2007
9	Monoclonal AntibodiesIBA 06/2024 - 01/2004
9	130-nm albumin-bound paclitaxelIBA 11/2021 - 07/2015
8	Immunoconjugates (Immunoconjugate)IBA 02/2024 - 02/2011
8	Phenobarbital (Luminal)FDA Link 12/2023 - 11/2011
8	Ado-Trastuzumab EmtansineIBA 01/2023 - 02/2011
8	B7-H1 AntigenIBA 01/2022 - 08/2017
7	eribulin FDA Link 10/2023 - 09/2017
7	talazoparibIBA 10/2023 - 01/2018
7	Progesterone Receptors (Progesterone Receptor)IBA 09/2023 - 04/2007
7	Immune Checkpoint InhibitorsIBA 01/2023 - 12/2016
7	Vinorelbine (Navelbine)FDA LinkGeneric 10/2022 - 01/2004
7	etirinotecan pegolIBA 01/2022 - 11/2015
7	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 08/2005
7	TOR Serine-Threonine KinasesIBA 01/2020 - 02/2012
6	LigandsIBA 05/2024 - 01/2004
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2023 - 02/2007
6	neratinibIBA 10/2023 - 05/2019
6	ribociclibIBA 09/2023 - 02/2016
6	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2018
6	ixabepilone (BMS 247550)FDA Link 01/2020 - 06/2013
5	Proteins (Proteins, Gene)FDA Link 05/2024 - 10/2021
5	Circulating Tumor DNAIBA 03/2024 - 01/2018
5	Messenger RNA (mRNA)IBA 12/2023 - 01/2020
5	PlatinumIBA 11/2021 - 06/2015
4	Surface Antigens (Surface Antigen)IBA 02/2024 - 01/2021
4	Irinotecan (Camptosar)FDA LinkGeneric 10/2022 - 01/2019
4	atezolizumabIBA 11/2021 - 11/2018
4	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2021 - 02/2007
4	Progesterone FDA LinkGeneric 01/2020 - 01/2010
4	SteroidsIBA 01/2020 - 01/2016
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020 - 02/2016
4	Palonosetron (Aloxi)FDA Link 01/2019 - 02/2013
4	Angiogenesis InhibitorsIBA 10/2018 - 08/2005
3	AntigensIBA 06/2024 - 01/2015
3	gedatolisibIBA 04/2024 - 01/2023
3	Cell-Free Nucleic AcidsIBA 03/2024 - 01/2021

Therapy/Procedure

158	Therapeutics 06/2024 - 12/2003
121	Drug Therapy (Chemotherapy) 05/2024 - 12/2003
33	Neoadjuvant Therapy 04/2024 - 12/2004
13	Drug Tapering 04/2024 - 08/2005
8	Adjuvant Chemotherapy 06/2022 - 12/2003
7	Aftercare (After-Treatment) 06/2023 - 11/2011
6	Immunotherapy 04/2024 - 01/2021
6	Radiotherapy 02/2024 - 01/2018